Skip to main content
Top
Published in: BMC Women's Health 1/2015

Open Access 01-12-2015 | Research article

Management of musculoskeletal tumors during pregnancy: a retrospective study

Authors: Lukas K. Postl, Guntmar Gradl, Rüdiger von Eisenhart-Rothe, Andreas Toepfer, Florian Pohlig, Rainer Burgkart, Hans Rechl, Chlodwig Kirchhoff

Published in: BMC Women's Health | Issue 1/2015

Login to get access

Abstract

Background

In recent years, scientific research has increasingly focused on malignancies during pregnancy. However, the development of musculoskeletal tumors during pregnancy has only been the subject of a few studies so far. The primary aim of this study was to identify the incidence of sarcomas during pregnancy at our musculoskeletal tumor center (MSTC). Secondarily we intended to analyze these cases and discuss possible recommendations regarding diagnostic work-up as well as therapy on the basis of the literature.

Methods

All female patients who had been treated for soft tissue or bone sarcoma at our academic MSTC in the period between the years 2002 and 2010 were screened retrospectively for anamnestic annotations of pregnancy or records of pregnancy in the obstetrical database of our university hospital. The patients who met the criteria for inclusion (diagnosed sarcoma and pregnancy) were enrolled. For every pregnant patient two age-matched female control patients that suffered from tumors with the same histologic type were included.

Results

In the period between 2002 and 2010, 240 female patients between the age of 16 and 45 were treated for sarcoma. In eight out of the 240 cases the tumor disease developed or progressed during pregnancy. The delay in diagnosis was approximately eight months and turned out to be significantly higher for pregnant patients compared to non- pregnant controls. Each woman’s tumor was misdiagnosed at least once.

Conclusions

Diagnostic follow-up of pregnant women presenting with a growing or painful mass, which is suspected to be a musculoskeletal tumor, should be performed at a specialized tumor center. We recommend a multidisciplinary approach and discussing all possible consequences for mother and child intensively in accordance with the available literature.
Literature
1.
go back to reference Lukanova A, Surcel HM, Lundin E, Kaasila M, Lakso HA, Schock H, et al. Circulating estrogens and progesterone during primiparous pregnancies and risk of maternal breast cancer. Int J Cancer. 2012 Feb 15;130(4):910-20 Lukanova A, Surcel HM, Lundin E, Kaasila M, Lakso HA, Schock H, et al. Circulating estrogens and progesterone during primiparous pregnancies and risk of maternal breast cancer. Int J Cancer. 2012 Feb 15;130(4):910-20
2.
go back to reference Chen T, Surcel HM, Lundin E, Kaasila M, Lakso HA, Schock H, et al. Circulating sex steroids during pregnancy and maternal risk of non-epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2011;20(2):324–36.CrossRefPubMed Chen T, Surcel HM, Lundin E, Kaasila M, Lakso HA, Schock H, et al. Circulating sex steroids during pregnancy and maternal risk of non-epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2011;20(2):324–36.CrossRefPubMed
3.
go back to reference Coenegrachts L, Maes C, Torrekens S, Van Looveren R, Mazzone M, Guise TA, et al. Anti-placental growth factor reduces bone metastasis by blocking tumor cell engraftment and osteoclast differentiation. Cancer Res. 2010;70(16):6537–47.CrossRefPubMed Coenegrachts L, Maes C, Torrekens S, Van Looveren R, Mazzone M, Guise TA, et al. Anti-placental growth factor reduces bone metastasis by blocking tumor cell engraftment and osteoclast differentiation. Cancer Res. 2010;70(16):6537–47.CrossRefPubMed
4.
go back to reference Cardonick E, Usmani A, Ghaffar S. Perinatal outcomes of a pregnancy complicated by cancer, including neonatal follow-up after in utero exposure to chemotherapy: results of an international registry. Am J Clin Oncol. 2010;33(3):221–8.PubMed Cardonick E, Usmani A, Ghaffar S. Perinatal outcomes of a pregnancy complicated by cancer, including neonatal follow-up after in utero exposure to chemotherapy: results of an international registry. Am J Clin Oncol. 2010;33(3):221–8.PubMed
6.
go back to reference Brewer M, Kueck A, Runowicz CD. Chemotherapy in pregnancy. Clin Obstet Gynecol. 2011;54(4):602–18.CrossRefPubMed Brewer M, Kueck A, Runowicz CD. Chemotherapy in pregnancy. Clin Obstet Gynecol. 2011;54(4):602–18.CrossRefPubMed
7.
go back to reference Cardonick E, Bhat A, Gilmandyar D, Somer R. Maternal and fetal outcomes of taxane chemotherapy in breast and ovarian cancer during pregnancy: case series and review of the literature. Ann Oncol. 2012;23(12):3016–23.CrossRefPubMed Cardonick E, Bhat A, Gilmandyar D, Somer R. Maternal and fetal outcomes of taxane chemotherapy in breast and ovarian cancer during pregnancy: case series and review of the literature. Ann Oncol. 2012;23(12):3016–23.CrossRefPubMed
8.
go back to reference Maxwell C, Barzilay B, Shah V, Wunder JS, Bell R, Farine D. Maternal and neonatal outcomes in pregnancies complicated by bone and soft-tissue tumors. Obstet Gynecol. 2004;104(2):344–8.CrossRefPubMed Maxwell C, Barzilay B, Shah V, Wunder JS, Bell R, Farine D. Maternal and neonatal outcomes in pregnancies complicated by bone and soft-tissue tumors. Obstet Gynecol. 2004;104(2):344–8.CrossRefPubMed
9.
go back to reference Merimsky O, Inbar M, Issakov J, Kollender Y, Flusser G, Meller I, et al. Gestation-related malignant musculoskeletal tumors. Isr Med Assoc J. 2003;5(4):264–7.PubMed Merimsky O, Inbar M, Issakov J, Kollender Y, Flusser G, Meller I, et al. Gestation-related malignant musculoskeletal tumors. Isr Med Assoc J. 2003;5(4):264–7.PubMed
10.
go back to reference Molho RB, Kollender Y, Issakov J, Bickels J, Flusser G, Azem F, et al. The complexity of management of pregnancy-associated malignant soft tissue and bone tumors. Gynecol Obstet Invest. 2008;65(2):89–95.CrossRefPubMed Molho RB, Kollender Y, Issakov J, Bickels J, Flusser G, Azem F, et al. The complexity of management of pregnancy-associated malignant soft tissue and bone tumors. Gynecol Obstet Invest. 2008;65(2):89–95.CrossRefPubMed
11.
go back to reference The grading of soft tissue sarcomas. Results of a clinicohistopathologic correlation in a series of 163 cases. Costa J, Wesley RA, Glatstein E, Rosenberg SA Cancer. 1984 Feb 1; 53(3):530-41. The grading of soft tissue sarcomas. Results of a clinicohistopathologic correlation in a series of 163 cases. Costa J, Wesley RA, Glatstein E, Rosenberg SA Cancer. 1984 Feb 1; 53(3):530-41.
12.
go back to reference Muller C, Huber W, Imhof H, Kainberger F. [The role of projectional radiography in the detection of primary malignant and indeterminate bone neoplasms]. Röfo. 2005;177(2):210–6.PubMed Muller C, Huber W, Imhof H, Kainberger F. [The role of projectional radiography in the detection of primary malignant and indeterminate bone neoplasms]. Röfo. 2005;177(2):210–6.PubMed
13.
go back to reference Bruns J, Delling G, Henne-Bruns D, Hossfeld DK. Biopsy of tumors of the musculoskeletal system. Dtsch Arztebl Int. 2008;105(27):492–7.PubMedPubMedCentral Bruns J, Delling G, Henne-Bruns D, Hossfeld DK. Biopsy of tumors of the musculoskeletal system. Dtsch Arztebl Int. 2008;105(27):492–7.PubMedPubMedCentral
14.
go back to reference Grimer RJ, Briggs TW. Earlier diagnosis of bone and soft-tissue tumours. J Bone Joint Surg (Br). 2010;92(11):1489–92.CrossRef Grimer RJ, Briggs TW. Earlier diagnosis of bone and soft-tissue tumours. J Bone Joint Surg (Br). 2010;92(11):1489–92.CrossRef
15.
go back to reference Taylor WS, Grimer RJ, Carter SR, Tillman RM, Abudu A, Jeys L. “Two-week waits”-are they leading to earlier diagnosis of soft-tissue sarcomas? Sarcoma. 2010;2010:1-3 Taylor WS, Grimer RJ, Carter SR, Tillman RM, Abudu A, Jeys L. “Two-week waits”-are they leading to earlier diagnosis of soft-tissue sarcomas? Sarcoma. 2010;2010:1-3
17.
go back to reference Bauer HC, Trovik CS, Alvegard TA, Berlin O, Erlanson M, Gustafson P, et al. Monitoring referral and treatment in soft tissue sarcoma: study based on 1,851 patients from the Scandinavian Sarcoma Group Register. Acta Orthop Scand. 2001;72(2):150–9.CrossRefPubMed Bauer HC, Trovik CS, Alvegard TA, Berlin O, Erlanson M, Gustafson P, et al. Monitoring referral and treatment in soft tissue sarcoma: study based on 1,851 patients from the Scandinavian Sarcoma Group Register. Acta Orthop Scand. 2001;72(2):150–9.CrossRefPubMed
18.
go back to reference Gronchi A, Lo Vullo S, Colombo C, Collini P, Stacchiotti S, Mariani L, et al. Extremity soft tissue sarcoma in a series of patients treated at a single institution: local control directly impacts survival. Ann Surg. 2010;251(3):506–11.CrossRefPubMed Gronchi A, Lo Vullo S, Colombo C, Collini P, Stacchiotti S, Mariani L, et al. Extremity soft tissue sarcoma in a series of patients treated at a single institution: local control directly impacts survival. Ann Surg. 2010;251(3):506–11.CrossRefPubMed
19.
go back to reference Siddique J, Lauderdale DS, VanderWeele TJ, Lantos JD. Trends in prenatal ultrasound use in the United States: 1995 to 2006. Med Care. 2009;47(11):1129–35.CrossRefPubMed Siddique J, Lauderdale DS, VanderWeele TJ, Lantos JD. Trends in prenatal ultrasound use in the United States: 1995 to 2006. Med Care. 2009;47(11):1129–35.CrossRefPubMed
20.
go back to reference Alcazar JL, Jurado M. Three-dimensional ultrasound for assessing women with gynecological cancer: a systematic review. Gynecol Oncol. 2011;120(3):340–6.CrossRefPubMed Alcazar JL, Jurado M. Three-dimensional ultrasound for assessing women with gynecological cancer: a systematic review. Gynecol Oncol. 2011;120(3):340–6.CrossRefPubMed
21.
go back to reference Chen MM, Coakley FV, Kaimal A, Laros Jr RK. Guidelines for computed tomography and magnetic resonance imaging use during pregnancy and lactation. Obstet Gynecol. 2008;112(2 Pt 1):333–40.CrossRefPubMed Chen MM, Coakley FV, Kaimal A, Laros Jr RK. Guidelines for computed tomography and magnetic resonance imaging use during pregnancy and lactation. Obstet Gynecol. 2008;112(2 Pt 1):333–40.CrossRefPubMed
22.
go back to reference Shellock FG, Crues JV. MR procedures: biologic effects, safety, and patient care. Radiology. 2004;232(3):635–52.CrossRefPubMed Shellock FG, Crues JV. MR procedures: biologic effects, safety, and patient care. Radiology. 2004;232(3):635–52.CrossRefPubMed
23.
go back to reference Kanal E, Barkovich AJ, Bell C, Borgstede JP, Bradley Jr WG, Froelich JW, et al. ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol. 2007;188(6):1447–74.CrossRefPubMed Kanal E, Barkovich AJ, Bell C, Borgstede JP, Bradley Jr WG, Froelich JW, et al. ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol. 2007;188(6):1447–74.CrossRefPubMed
24.
go back to reference Mazonakis M, Varveris H, Fasoulaki M, Damilakis J. Radiotherapy of Hodgkin’s disease in early pregnancy: embryo dose measurements. Radiother Oncol. 2003;66(3):333–9.CrossRefPubMed Mazonakis M, Varveris H, Fasoulaki M, Damilakis J. Radiotherapy of Hodgkin’s disease in early pregnancy: embryo dose measurements. Radiother Oncol. 2003;66(3):333–9.CrossRefPubMed
25.
go back to reference Nakagawa K, Aoki Y, Kusama T, Ban N, Nakagawa S, Sasaki Y. Radiotherapy during pregnancy: effects on fetuses and neonates. Clin Ther. 1997;19(4):770–7.CrossRefPubMed Nakagawa K, Aoki Y, Kusama T, Ban N, Nakagawa S, Sasaki Y. Radiotherapy during pregnancy: effects on fetuses and neonates. Clin Ther. 1997;19(4):770–7.CrossRefPubMed
26.
go back to reference Cardonick E. Treatment of maternal cancer and fetal development. Lancet Oncol. 2012;13(3):218–20.CrossRefPubMed Cardonick E. Treatment of maternal cancer and fetal development. Lancet Oncol. 2012;13(3):218–20.CrossRefPubMed
27.
go back to reference Kal HB, Struikmans H. Radiotherapy during pregnancy: fact and fiction. Lancet Oncol. 2005;6(5):328–33.CrossRefPubMed Kal HB, Struikmans H. Radiotherapy during pregnancy: fact and fiction. Lancet Oncol. 2005;6(5):328–33.CrossRefPubMed
29.
go back to reference Liu LX, Arany Z. Maternal Cardiac Metabolism in Pregnancy. Cardiovasc Res. 2014 Mar 15;101(4):545-53. Liu LX, Arany Z. Maternal Cardiac Metabolism in Pregnancy. Cardiovasc Res. 2014 Mar 15;101(4):545-53.
30.
go back to reference Ni Mhuireachtaigh R, O’Gorman DA. Anesthesia in pregnant patients for nonobstetric surgery. J Clin Anesth. 2006;18(1):60–6.CrossRefPubMed Ni Mhuireachtaigh R, O’Gorman DA. Anesthesia in pregnant patients for nonobstetric surgery. J Clin Anesth. 2006;18(1):60–6.CrossRefPubMed
32.
go back to reference Luis SA, Christie DR, Kaminski A, Kenny L, Peres MH. Pregnancy and radiotherapy: management options for minimising risk, case series and comprehensive literature review. J Med Imaging Radiat Oncol. 2009;53(6):559–68.CrossRefPubMed Luis SA, Christie DR, Kaminski A, Kenny L, Peres MH. Pregnancy and radiotherapy: management options for minimising risk, case series and comprehensive literature review. J Med Imaging Radiat Oncol. 2009;53(6):559–68.CrossRefPubMed
33.
go back to reference Han B, Bednarz B, Xu XG. A study of the shielding used to reduce leakage and scattered radiation to the fetus in a pregnant patient treated with a 6-MV external X-ray beam. Health Phys. 2009;97(6):581–9.CrossRefPubMedPubMedCentral Han B, Bednarz B, Xu XG. A study of the shielding used to reduce leakage and scattered radiation to the fetus in a pregnant patient treated with a 6-MV external X-ray beam. Health Phys. 2009;97(6):581–9.CrossRefPubMedPubMedCentral
34.
go back to reference Josipovic M, Nystrom H, Kjaer-Kristoffersen F. IMRT in a pregnant patient: how to reduce the fetal dose? Med Dosim. 2009;34(4):301–10.CrossRefPubMed Josipovic M, Nystrom H, Kjaer-Kristoffersen F. IMRT in a pregnant patient: how to reduce the fetal dose? Med Dosim. 2009;34(4):301–10.CrossRefPubMed
35.
go back to reference Triunfo S, Scambia G. Cancer in pregnancy: diagnosis, treatment and neonatal outcome. Minerva Ginecol. 2014;66(3):325–34.PubMed Triunfo S, Scambia G. Cancer in pregnancy: diagnosis, treatment and neonatal outcome. Minerva Ginecol. 2014;66(3):325–34.PubMed
36.
go back to reference Azim Jr HA, Peccatori FA, Pavlidis N. Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: Solid tumors. Cancer Treat Rev. 2010;36(2):101–9.CrossRefPubMed Azim Jr HA, Peccatori FA, Pavlidis N. Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: Solid tumors. Cancer Treat Rev. 2010;36(2):101–9.CrossRefPubMed
37.
go back to reference Cardonick EH, Gringlas MB, Hunter K, Greenspan J. Development of children born to mothers with cancer during pregnancy: comparing in utero chemotherapy-exposed children with nonexposed controls. Am J Obstet Gynecol. 2015 May 212(5):658.e1-8. Cardonick EH, Gringlas MB, Hunter K, Greenspan J. Development of children born to mothers with cancer during pregnancy: comparing in utero chemotherapy-exposed children with nonexposed controls. Am J Obstet Gynecol. 2015 May 212(5):658.e1-8.
38.
go back to reference Dotters-Katz S, McNeil M, Limmer J, Kuller J. Cancer and Pregnancy: The Clinician’s Perspective. Obstet Gynecol Surv. 2014;69(5):277–86.CrossRefPubMed Dotters-Katz S, McNeil M, Limmer J, Kuller J. Cancer and Pregnancy: The Clinician’s Perspective. Obstet Gynecol Surv. 2014;69(5):277–86.CrossRefPubMed
Metadata
Title
Management of musculoskeletal tumors during pregnancy: a retrospective study
Authors
Lukas K. Postl
Guntmar Gradl
Rüdiger von Eisenhart-Rothe
Andreas Toepfer
Florian Pohlig
Rainer Burgkart
Hans Rechl
Chlodwig Kirchhoff
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Women's Health / Issue 1/2015
Electronic ISSN: 1472-6874
DOI
https://doi.org/10.1186/s12905-015-0204-3

Other articles of this Issue 1/2015

BMC Women's Health 1/2015 Go to the issue